N/A
N=104
Effectiveness and Safety Comparison of Lunaphil Ultra (Hyaluronic Acid, by Espad Pharmed Co.) Versus Juvederm Ultra 4® (Hyaluronic Acid, by Allergan Co.) in Nasolabial Folds (NLFs) Management
Moderate or Severe Nasolabial Folds
Bottom Line
View on ClinicalTrials.gov: NCT06509477 ↗Enrolled (actual)
104
Serious AEs
0.0%
Results posted
Feb 2026
Primary outcome: Primary: Mean Level of Improvement From Baseline in NLF Severity Score by Wrinkle Severity Rating Scale (WSRS) — -0.80; -0.81; -0.73; -0.74 score on a scale — p=>0.99
Study Design & Population
- Study type
- Interventional
- Phase
- N/A
- Interventions
- Hyaluronic acid Lunaphil Ultra (by Espad Pharmed Co.) (Device); Hyaluronic acid Juvederm Ultra 4® (by Allergan Co.) (Device)
- Age
- Adult, Older Adult · 30+ yrs
- Sex
- All
- Sponsor
- Espad Pharmed
- Primary completion
- Nov 2023
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Mean Level of Improvement From Baseline in NLF Severity Score by Wrinkle Severity Rating Scale (WSRS) |
-0.80; -0.81; -0.73; -0.74 | >0.99 |
| SECONDARY Number of Subjects With an Improved Score From Baseline Based on Physician Global Aesthetic Improvement Scale (PGAIS) |
66; 66; 79; 79 | >0.99 |
| SECONDARY Number of NLFs Maintaining a Clinically Significant Improvement in NLF Severity Score by Wrinkle Severity Rating Scale (WSRS) |
43; 43 | >0.99 |
| SECONDARY The Injected Volume to Obtain Optimal Aesthetic Result |
0.90; 0.88 | 0.49 |
| SECONDARY The Number of NLFs Receiving Touch-up Treatment |
74; 69 | 0.33 |
| SECONDARY Evaluation of Adverse Events During 24 Weeks |
3; 5 | — |
Summary
Rationale and background: Skin aging is a complex process that results in various changes in the skin, including wrinkles, sun spots, and sagging skin. The NLF is a natural change that becomes more prominent with aging and significantly affects the beauty of the facial skin. Dermal fillers, particularly hyaluronic acid (HA) fillers, are commonly used to correct these signs of aging. This study aimed to compare the effectiveness and safety of Lunaphil Ultra with Juvederm Ultra 4® for treating NLFs.
Primary objective: Effectiveness assessment of Lunaphil Ultra Secondary objectives: Effectiveness and safety assessment of Lunaphil Ultra Study design: This is a randomized, double-masked, active controlled, within-subject, and equivalency clinical trial.
Setting: Subjects were treated with Lunaphil Ultra in one NLF and Juvederm Ultra 4® in the opposite NLF.
Eligibility Criteria
Inclusion Criteria
- Subjects ≥ 30 years of age
- Visible bilateral NLFs that were approximately symmetrical and had an equal severity ranging from moderate to severe (assessed at the deepest part)
- Able to follow study instructions and likely to complete all required visits
- Signed informed consent
Exclusion Criteria
- History of bleeding disorders or participants receiving or recently exposed (≤ 3 weeks) to continuous treatment with thrombolytics, anticoagulants, platelet inhibitors, or NSAIDs
- Acute herpetic eruption
- Known susceptibility to keloid formation, hypertrophic scarring or clinically significant skin pigmentation disorders
- Known sensitivity to local anesthetics of the amide type (such as lidocaine), history of hypersensitivity to gram-positive bacterial proteins, history of multiple severe allergies, history of anaphylactic shock
- Known hypersensitivity to any component of the study products or excipients (like hyaluronic acid)
- History of receiving immune therapy or a history of autoimmune disease
- History of active chronic debilitating systemic disease
- History of connective tissue disease, history of malignancy (except for non-melanoma skin cancer) within the last 5 years
- Clinically significant active dermatologic disorders within the last 6 months
- Use of oral retinoids, over-the-counter (OTC) or prescription antiwrinkle treatments, microdermabrasion, or chemical peels in the NLF area within the last 4 weeks or intention to use them during the study
- Any prior cosmetic procedure or tissue augmentation at the NLF injection site within 1 year before study entry (or intent to undergo such a procedure during the study)
- Pregnancy or breastfeeding
Data sourced from ClinicalTrials.gov (NCT06509477). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.